Compare WAY & BLCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WAY | BLCO |
|---|---|---|
| Founded | 1999 | 1853 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | | Ophthalmic Goods |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.7B | 6.0B |
| IPO Year | 2024 | 2022 |
| Metric | WAY | BLCO |
|---|---|---|
| Price | $34.25 | $17.27 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 15 | 14 |
| Target Price | ★ $46.53 | $17.31 |
| AVG Volume (30 Days) | ★ 1.8M | 361.8K |
| Earning Date | 02-17-2026 | 02-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.62 | N/A |
| Revenue | $1,039,842,000.00 | ★ $4,976,000,000.00 |
| Revenue This Year | $16.69 | $8.06 |
| Revenue Next Year | $17.44 | $5.79 |
| P/E Ratio | $55.47 | ★ N/A |
| Revenue Growth | ★ 14.76 | 6.23 |
| 52 Week Low | $29.40 | $10.45 |
| 52 Week High | $48.11 | $18.14 |
| Indicator | WAY | BLCO |
|---|---|---|
| Relative Strength Index (RSI) | 56.02 | 58.68 |
| Support Level | $31.13 | $16.22 |
| Resistance Level | $33.72 | $17.55 |
| Average True Range (ATR) | 0.82 | 0.35 |
| MACD | 0.28 | -0.02 |
| Stochastic Oscillator | 98.45 | 78.20 |
Waystar Holding Corp is a provider of mission-critical cloud technology to healthcare organizations. its enterprise-grade platform transforms the complex and disparate processes comprising healthcare payments received by healthcare providers from payers and patients, from pre-service engagement through post-service remittance and reconciliation. its platform enhances data integrity, eliminates manual tasks, and improves claim and billing accuracy, which results in transparency, reduced labor costs, and faster, more accurate reimbursement and cash flow. The market for solutions extends throughout the United States and includes Puerto Rico and other USA Territories.
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.